{"id":51294,"date":"2021-05-09T16:48:19","date_gmt":"2021-05-09T20:48:19","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=51294"},"modified":"2023-06-06T18:09:03","modified_gmt":"2023-06-06T22:09:03","slug":"promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/","title":{"rendered":"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma"},"content":{"rendered":"
\"natalie-grover\"<\/a>
Natalie Grover, MD<\/figcaption><\/figure>\n

Natalie Grover<\/a>, MD, assistant professor in the division of hematology and clinical director of the cell therapy program in the Lineberger Comprehensive Cancer Center, discusses her research on anti-CD30 CAR-T therapy for patients with relapsed\/refractory Hodgkin lymphoma in a new video featured on the Oncology Learning Network<\/a>.<\/p>\n

Following is an excerpt from the transcript:<\/p>\n

“CAR-T cells targeting CD19 have shown remarkable efficacy in B\u2011cell lymphomas. This has sparked interest in exploring other targets in lymphoma. CD30 is universally expressed in Reed\u2011Sternberg cells. These are the malignant cells in classical Hodgkin lymphoma.<\/p>\n

“In addition, targeting CD30 has minimal on\u2011target, off\u2011tumor toxicity because it has low expression in normal tissue. Its efficacy and safety as a target has also been demonstrated by the success of the drug brentuximab vedotin.<\/p>\n

“Although the majority of patients with Hodgkin lymphoma are cured with first\u2011line therapy, a proportion of patients have relapsed or refractory disease, and prognosis is worse for those patients.”<\/p>\n

Grover says CD30\u2011directed CAR-T cells have promising clinical activity in relapsed or refractory Hodgkin lymphoma with a good safety profile and should be explored further in larger trials.<\/p>\n

Read the transcript or watch the video<\/a>.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Natalie Grover, MD, assistant professor in the division of hematology and clinical director of the cell therapy program in the Lineberger Comprehensive Cancer Center, discusses her research on anti-CD30 CAR-T therapy for patients with relapsed\/refractory Hodgkin lymphoma in a new video featured on the Oncology Learning Network. Following is an excerpt from the transcript: “CAR-T … Read more<\/a><\/p>\n","protected":false},"author":69419,"featured_media":46957,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[520,2],"tags":[630],"class_list":["post-51294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hematology","category-news","tag-630","odd"],"acf":[],"yoast_head":"\nPromising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"Natalie Grover, MD, assistant professor in the division of hematology and clinical director of the cell therapy program in the Lineberger Comprehensive Cancer Center, discusses her research on anti-CD30 CAR-T therapy for patients with relapsed\/refractory Hodgkin lymphoma in a new video featured on the Oncology Learning Network. Following is an excerpt from the transcript: “CAR-T … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UNCDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-09T20:48:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T22:09:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1707\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Morris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Morris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\"},\"author\":{\"name\":\"Kim Morris\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"headline\":\"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma\",\"datePublished\":\"2021-05-09T20:48:19+00:00\",\"dateModified\":\"2023-06-06T22:09:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\"},\"wordCount\":218,\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg\",\"keywords\":[\"2021\"],\"articleSection\":[\"Hematology\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\",\"name\":\"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg\",\"datePublished\":\"2021-05-09T20:48:19+00:00\",\"dateModified\":\"2023-06-06T22:09:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg\",\"width\":1707,\"height\":2560,\"caption\":\"Natalie Grover, MD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\",\"name\":\"Kim Morris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"caption\":\"Kim Morris\"},\"description\":\"Medicine - Dept of\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/","og_locale":"en_US","og_type":"article","og_title":"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma | Department of Medicine","og_description":"Natalie Grover, MD, assistant professor in the division of hematology and clinical director of the cell therapy program in the Lineberger Comprehensive Cancer Center, discusses her research on anti-CD30 CAR-T therapy for patients with relapsed\/refractory Hodgkin lymphoma in a new video featured on the Oncology Learning Network. Following is an excerpt from the transcript: “CAR-T … Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/UNCDeptMedicine","article_published_time":"2021-05-09T20:48:19+00:00","article_modified_time":"2023-06-06T22:09:03+00:00","og_image":[{"width":1707,"height":2560,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg","type":"image\/jpeg"}],"author":"Kim Morris","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Kim Morris","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/"},"author":{"name":"Kim Morris","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"headline":"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma","datePublished":"2021-05-09T20:48:19+00:00","dateModified":"2023-06-06T22:09:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/"},"wordCount":218,"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg","keywords":["2021"],"articleSection":["Hematology","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/","name":"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg","datePublished":"2021-05-09T20:48:19+00:00","dateModified":"2023-06-06T22:09:03+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg","width":1707,"height":2560,"caption":"Natalie Grover, MD"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/promising-therapy-for-patients-with-relapsed-refractory-hodgkin-lymphoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"Promising Therapy For Patients With Relapsed\/Refractory Hodgkin Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529","name":"Kim Morris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","caption":"Kim Morris"},"description":"Medicine - Dept of","url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1-200x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1-768x1152.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1-683x1024.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2020\/10\/Grover-Natalie-Faculty-Photo-scaled-1-150x150.jpg","featured_image_alt":"Natalie Grover, MD","category_details":[{"name":"Hematology","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/hematology\/"},{"name":"News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/news\/"}],"tag_details":[{"name":"2021","link":"https:\/\/www.med.unc.edu\/medicine\/news\/tag\/2021\/"}],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/51294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/69419"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=51294"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/51294\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/46957"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=51294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=51294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=51294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}